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Abstract 
Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and develop-
ment is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective 
anti-cancer therapies available and partly due to the limited accuracy of biomarkers to report on cell proliferation 
rates in patients. Accordingly, accurate methods of diagnosing, staging and assessing response to therapy are crucial 
to improve patient outcomes. One effective way of assessing cell proliferation is to employ non-invasive evaluation 
using 3’-deoxy-3’-[18F]fluorothymidine  ([18F]FLT) positron emission tomography  [18F]FLT-PET.  [18F]FLT, unlike the most 
commonly used PET tracer  [18F]fluorodeoxyglucose  ([18F]FDG), can specifically report on cell proliferation and does 
not accumulate in inflammatory cells. Therefore, this radiotracer could exhibit higher specificity in diagnosis and 
staging, along with more accurate monitoring of therapy response at early stages in the treatment cycle. This review 
summarises and evaluates published studies on the clinical use of  [18F]FLT to diagnose, stage and assess response to 
therapy in lung cancer.
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Key points
• [18F]FLT is a useful surrogate biomarker of cell prolif-
eration.
• [18F]FLT has higher specificity than  [18F]FDG for 
diagnosing or staging lung cancer.
• [18F]FLT has lower sensitivity than  [18F]FDG for 
diagnosing or staging lung cancer.
• [18F]FLT has good predictive values for assessing 
response to radiotherapy or chemoradiotherapy.
• [18F]FLT looks especially useful for assessing early 
response to targeted therapies.
Background
Lung cancer (LC) remains the leading cause of cancer-
related mortality worldwide, accounting for about 18.4 
% of all cancer cases in 2018. It ranks first in mortality 
and incidence in men. In women it has the second high-
est mortality and the third highest incidence [1]. LC is 
subcategorised histologically into small cell lung can-
cer (SCLC) and non-small cell lung cancer (NSCLC), of 
which adenocarcinoma (ADC), squamous cell carcinoma 
(SqCC) and large cell lung carcinoma (LCC) represents 
almost 80 % of diagnosed cases [2]. These subcategories 
show different growth patterns and might be associated 
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NSCLC can be stratified according to the tumour size, 
nodal involvement and metastases (TNM). SCLC is usu-
ally divided into  limited  or  extensive  disease, although 
the TNM system has been adopted by some clinical com-
mittees. These models, such as those provided by the 
Veterans Administration Lung Study Group and later 
modified by the International Association for the Study 
of Lung Cancer (IASLC), have proven useful to guide 
prognosis and patient stratification for therapy [4].
Uncontrolled cell proliferation is a fundamental hall-
mark of malignant tumour growth. The biomarker Ki-67 
is considered the gold standard for assessment of cell 
proliferation due to the strong correlation between the 
cell proliferation rate and Ki67 expression in cells [5, 
6]. However, it exhibits several potential drawbacks in 
the clinic, including the requirement for invasive col-
lection of biopsies and possible sampling bias, due to 
poorly representative biopsies collected from hetero-
geneous tumours [7]. Over the past few decades, non-
invasive positron emission tomography (PET) imaging 
has played an increasingly important role in LC manage-
ment.  [18F]Fluorodeoxyglucose  ([18F]FDG) is the most 
widely used radiotracer in PET. It is a glucose analogue 
which monitors glucose metabolism, based on the con-
cept that tumour cells take up significantly higher levels 
of glucose than normal tissues. It has been a beneficial 
adjunct in characterisation of intermediate solitary lung 
nodules and pre-treatment detection and staging of dis-
tant metastases [8]. However,  [18F]FDG uptake is modu-
lated by multiple signalling pathways, so is not selective 
enough to specifically assess changes in the cell prolifera-
tion rate. Moreover, a meta-analysis of  [18F]FDG in LC 
showed its extreme heterogeneity in LC in pulmonary 
areas with inflammations [9].
The first PET radiotracer introduced for in vivo pro-
liferative imaging was 11C-labelled thymidine  ([11C]thy-
midine); however, its rapid degradation with a half-life 
time of only 20 min is a major limitation [10]. 3’-deoxy-
3’-[18F]fluorothymidine  ([18F]FLT) was therefore sub-
sequently employed, as this 18F-labelled thymidine 
analogue has a half-life of about 110 min.  [18F]FLT is 
initially phosphorylated by cytosolic thymidine kinase 1 
(TK1) into FLT-monophosphate and then subsequently 
further phosphorylated to make the diphosphate and 
triphosphate nucleotide (Fig.  1). TK1 is the principal 
enzyme that controls the rate of nucleotide recycling 
via the salvage pathway of DNA synthesis. After  [18F]
FLT is phosphorylated to the triphosphate analogue 
it cannot be further metabolised or incorporated into 
the DNA molecule. It is therefore trapped intracel-
lularly as its high hydrophilicity means that it cannot 
readily cross the cell membrane. This cell sequestration 
of  [18F]FLT is due to the substitution of the hydroxyl 
group at the 5’-end of thymidine, which is essential for 
Fig. 1 Summary of  [18F]FLT uptake mechanism into cells.  [18F]FLT sequestration in the cell after its phosphorylation by thymidine kinase 1 (TK1) into 
 [18F]FLT monophosphate  ([18F]FLT-MP),  [18F]FLT diphosphate  ([18F]FLT-DP) and  [18F]FLT triphosphate  ([18F]FLT-TP)
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ligation of DNA, with a fluorine-18 radionuclide. TK1 
expression levels increase dramatically in proliferating 
cells, and there is close correlation between expres-
sion of the enzyme and the cell proliferation rate [11, 
12]. Close correlation has also been observed between 
Ki-67 scoring and  [18F]FLT uptake in many tumour 
types [5], including LC [6]. Therefore,  [18F]FLT is a very 
plausible alternative to Ki-67 for assessing the prolif-
eration rate in tumours. It also offers the advantages 
of avoiding the need to collect invasive biopsies and 
allows evaluation of proliferation heterogeneity across 
the entire tumour, minimising both patient discomfort 
and sampling errors. Moreover,  [18F]FLT-PET is able to 
produce repeated 3D images for multiple cancer sites 
simultaneously, which is a distinct advantage for accu-
rately assessing response to therapy. Alternative prolif-
eration radiotracers have been also developed as direct 
biomarkers for DNA synthesis as they can be incor-
porated into DNA. This includes 2’-deoxy-2’-fluoro-
5-methyl-1-β-d-arabinofuranosyluracil  ([18F]FMAU) 
and 1-(2-deoxy-2-[18F]fluoro-β-d-arabinofuranosyl)-
5-bromouracil  ([18F]FBAU). However, these radiotrac-
ers are poor substrates for TK1 and show low uptake in 
highly proliferating tissue compared with  [18F]FLT. This 
probably reflects their phosphorylation by mitochon-
drial thymidine kinase 2 (TK2) rather than TK1 [13], 
making  [18F]FLT potentially superior to other prolifera-
tion radiotracers.
Relatively similar imaging protocols are followed in 
most  [18F]FLT-PET scans. No specific preparations are 
required by patients although it is advantageous if they 
are instructed to drink up to 1 L water before imaging 
to stimulate tracer excretion from the renal calyces [14, 
15]. The tracer dose administered ranges from 130 to 
550 MBq. Most protocols employ static scans, although 
some more involved studies use dynamic scans to obtain 
more complex datasets. Subtly different scan timings and 
imaging parameters such as field of view and reconstruc-
tion techniques are also performed. For PET/CT, the 
patient is usually positioned supine, with arms raised to 
minimise beam hardening. Image evaluation is usually 
performed by two or more nuclear medicine physicians 
blinded to patient’s data.
The aim of this literature review paper is to review the 
clinical value of  [18F]FLT-PET proliferative imaging for 
diagnosis, staging and assessing response to therapy in 
LC. A secondary objective is to analyse the uptake val-
ues of  [18F]FLT-PET in the various main LC sub-types 
in comparison with  [18F]FDG and whether there is any 
difference between the two tracers in these sub-types. 
This overview will further enable clinicians to bet-
ter understand the added value of  [18F]FLT for clinical 
management of LC and its proliferative pattern in com-
parison with  [18F]FDG in different LC sub-types.
Materials and methods
Search strategy
To identify all relevant publications, a systematic search 
of Scopus/PubMed databases was implemented from 
inception to 1st December 2020 using combinations of 
the following keywords: “positron emission tomography”, 
“PET”, “lung cancer”, “fluorothymidine” and “[18F]FLT”.
Selection process
All potentially relevant publications were screened for 
eligibility. Initially, titles and abstracts were screened and 
if necessary, the full texts were scrutinised as well. Stud-
ies were included if they met the following criteria:
1. It was an original study that investigated the perfor-
mance of  [18F]FLT-PET for diagnosing, staging or 
assessing therapy response in LC patients;
2. It involved patients with suspected or confirmed 
malignant lesions;
3. The patients underwent chemotherapy, radiotherapy, 
chemoradiotherapy or targeted therapy; and
4. Clinical outcome was assessed.
Studies were excluded if they:
1. Only involved animal or in vitro studies;
2. Were not written in English or were not accessible in 
full text; and
3. Involved certain publication types: case reports, 
reviews, legal cases, editorials, letters, interviews, and 
comments.
Statistical analysis of  [18F]FLT uptake versus  [18F]FDG 
uptake in lung cancer sub‑types
Statistical analysis was performed using SPSS software. 
The specific research questions posed were as follows:
Is there any difference between the mean  [18F]FDG 
and  [18F]FLT uptake values in lung cancer patients? Null 
hypothesis was that there is no difference. Analysis was 
done using an unpaired students t-test.
Is there any different in mean radiotracer uptake values 
between the different lung cancer sub-types? This test 
was performed independently for  [18F]FDG and  [18F]FLT. 
Null hypothesis was that there is no difference. Statistical 
analysis was performed using a 1-way ANOVA with tuk-
eys post hoc analysis and bootstrapping.
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Results
Search results
The literature search identified a total of 319 studies: 
210 in Scopus and 109 in PubMed. After removing the 
studies that were found in both databases, 221 studies 
remained. Figure 2 presents the flow chart of the search 
and selection procedure. Out of 221, only 31 studies were 
included as eligible, and out of these 31 studies, 17 stud-
ies were included for quantitative synthesis. A summary 
of  [18F]FLT-PET LC clinical studies and their findings is 
listed in Table 1 and 2.
Diagnosis studies
The past two decades have witnessed a growing atten-
tion to  [18F]FLT as a potential diagnostic to aid LC 
patient management. Imaging with  [18F]FLT has shown 
added benefit to diagnostic accuracy. Buck et al. (n = 30) 
and Vessel et al. (n = 10) introduced the clinical poten-
tial of  [18F]FLT in LC by demonstrating that the tracer 
accumulates primarily in malignant lesions, with minimal 
uptake in benign lesions. The latter study also showed 
 [18F]FLT maximum standardised uptake value (SUVmax) 
strongly correlates with both Ki-67 index and S-phase 
fraction (SPF), measured using flow cytometry [14, 16]. 
Further, Buck et  al. observed mean SUVmax of 5.2 in 
malignant tumours compared with no apparent uptake in 
benign tumours [16]. This observation was supported by 
another study which showed primary tumours exhibit-
ing almost identical  [18F]FLT uptake values [17]. Further-
more, Wang et al. (n = 55) observed significantly higher 
 [18F]FLT uptake (p < 0.05) in LC lesions compared with 
all other solitary pulmonary nodules, including tubercu-
losis, inflammatory and benign lesions, whereas tuber-
culosis showed similar  [18F]FDG-SUVmax (6.9) values to 
LC (6.8) [18]. In multiple comparative studies with  [18F]
FDG [18–21], higher specificity (ability to exclude non-
malignant lesions) was presented using  [18F]FLT. The 
imaging specificity of  [18F]FLT ranges from about 77% to 
Records idenfied through 
database searching
(n = 319)
Records aer duplicates removed
(n = 221) 
Records screened 
(n = 221)
Full-text arcles assessed for 
eligibility
(n = 49)
Arcles included in qualitave 
synthesis
(n = 31) 
Records excluded: 
(n = 172)























as not evaluang diagnosis, 
staging or therapy response
(n = 18)
Arcles included in quantave 
synthesis
(n = 17 out of 31)
Fig. 2 Flowchart of the search and selection process of studies
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99% versus about 50% to 84% for imaging with  [18F]FDG 
in a total number of 195 patients of all study cohorts 
combined.
On the other hand, the relatively low uptake of  [18F]FLT 
adversely affects its detection ability in comparison with 
 [18F]FDG. For example, Buck et al. exhibited the signifi-
cantly lower uptake of  [18F]FLT compared with  [18F]FDG 
(p < 0.05) [17]. Similar significant differences between 
 [18F]FLT and  [18F]FDG uptakes were also reported in 
a number of other studies [18–20, 22–26]. Also, lower 
sensitivity was shown with  [18F]FLT-PET compared with 
 [18F]FDG-PET. The sensitivity of  [18F]FLT-PET range was 
only 65%–83% versus 85%–97% for  [18F]FDG-PET in 195 
patients combined from the mentioned studies. Given 
the higher specificity of  [18F]FLT-PET but lower sensitiv-
ity in comparison with  [18F]FDG-PET, it was proposed 
that a combination of both  [18F]FLT and  [18F]FDG-PET 
could potentially provide better diagnostic performance 
than the individual tracers. Indeed, this strategy was 
conducted by a multicentre study consisted 55 patients 
with suspected LC [21], resulting in sensitivity improving 
from 87% (with  [18F]FDG alone) to 100% and specificity 
increasing from 77% (with  [18F]FLT alone) to approxi-
mately about 90%.
Proliferative imaging of lung cancer sub‑types with  [18F]
FLT versus  [18F]FDG
Histological uptake in this review showed that  [18F]
FLT-SUVmax is significantly lower than  [18F]FDG-SUV-
max across all LC histotypes (p < 0.0001), with different 
uptake values in the various histotypes.  [18F]FDG-SUV-
max, as illustrated in Fig.  3, demonstrated the greatest 
mean SUVmax in SCLC (12.03) followed by SqCC (9.38), 
LCC (8.60), and ADC (8.10). A comparison of  [18F]FDG-
SUVmax detected no significant difference in the 4 sub-
types of LC (p > 0.05), although the statistical power of 
this analysis is limited by the number of SCLC studies 
performed to date.
The highest  [18F]FLT-mean SUVmax was in SqCC 
(4.65) followed by LCC (4.07), ADC (3.82), and SCLC 
(2.39). A comparison of  [18F]FLT-SUVmax between the 
different histotypes observed that  [18F]FLT-SUVmax 
was significantly lower in SCLC than in SqCC (p < 0.05). 
Uptake patterns with both tracers in NSCLC sub-types 
are consistent with the proliferative patterns demon-
strated by Ki-67 in a previous study in the different sub-
types of NSCLC histology [26].
Staging studies
Staging of LC is another clinical application that has been 
evaluated in several studies. In general,  [18F]FLT-PET 
has failed to demonstrate better TNM staging than  [18F]
FDG-PET. Initially, a preliminary study in 2004 showed 
that, in comparison with clinical TNM staging,  [18F]
FLT may be limited;  [18F]FLT staging identified 9 out of 
17 patients incorrectly [15]. Buck et  al. compared  [18F]
FLT-PET with  [18F]FDG-PET for staging 47 patients with 
suspected malignant nodules. The clinical TNM stage 
according to histopathology was correctly identified in 
67% of  [18F]FLT scans compared with 85% of  [18F]FDG 
scans [17]. Furthermore, Yap et al. (n = 22) also evaluated 
 [18F]FLT staging in comparison with  [18F]FDG, taking 
histopathology data as a reference standard. According to 
histopathology, 3 patients were disease free, 10 patients 
were at early resectable stages and 7 were at late inoper-
able stages.  [18F]FLT overstaged two patients (9%) and 
understaged eight patients (36%) whereas  [18F]FDG over-
staged six patients (27%) and understaged three patients 
(14%) [46]. Likewise, Yang et  al. (n = 31) observed that 
more patients are understaged with  [18F]FLT and more 
patients are overstaged with  [18F]FDG. In this study, 
understaged patients represent 16% with  [18F]FLT and 
6% with  [18F]FDG and overstaged patients represent 6% 
with  [18F]FLT and 16% with  [18F]FDG [20].
In addition, sensitivity, specificity and accuracy of  [18F]
FLT for nodal involvement were evaluated in 5 studies in 
comparison with  [18F]FDG. The data showed clear differ-
ences between the two tracers. Buck et al. (n = 47) com-
pared  [18F]FLT-PET staging with  [18F]FDG-PET staging 
in 47 patients with suspected malignant nodules and 
found that the clinical TNM stage was correctly identi-
fied in 67% of  [18F]FLT scans compared with 85% of  [18F]
FDG scans [17]. Although both  [18F]FLT and  [18F]FDG 
showed 100% specificity for staging of lymph nodes in 
this study, the sensitivity and accuracy of  [18F]FDG was 
higher (77% and 83%) than those of  [18F]FLT (53% and 
67%). Another study of 31 NSCLC patients [20] demon-
strated even greater specificity and accuracy for  [18F]FLT 
in staging lymph nodes than  [18F]FDG but lower sensitiv-
ity than that of  [18F]FDG. The sensitivity, specificity and 
accuracy for  [18F]FLT were 65%, 85% and 93%, respec-
tively, whereas the equivalent  [18F]FDG values were 98%, 
84% and 84%, respectively [20]. In contrast, Yamamoto 
et al. (n = 34) showed the same sensitivity (57%) for both 
tracers but higher specificity and accuracy (93% and 
85%) for  [18F]FLT versus 78% and 74% for  [18F]FDG [19]. 
Moreover, Xu et al. (n = 14) reported better sensitivity, 
specificity and accuracy for  [18F]FLT (85%, 93% and 85%, 
respectively) than for  [18F]FDG (93%, 78% and 84%) [26]. 
However, taken together, the weighted mean for sensitiv-
ity, specificity and accuracy in all of these studies for  [18F]
FLT are 61%, 94%, and 80%, respectively, and for  [18F]
FDG are 79%, 88% and 80%, respectively.
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Studies assessing therapy response
Chemotherapy
Three studies have investigated the potential of  [18F]FLT 
for assessing chemotherapy and the findings were not 
promising. Frings et al. [28] showed that change in  [18F]
FLT uptake  4 hours after treatment with pemetrexed, 
an inhibitor of thymidylate synthase, was neither signifi-
cantly correlated with time to progression (TTP) nor with 
overall survival (OS) in 14 patients (p = 0.96 and 0.43, 
respectively). Likewise, McHugh et  al. [30] investigated 
the effect of dexamethasone, a drug used to mitigate side 
effects of chemotherapy, on pemetrexed efficacy. They 
demonstrated that  [18F]FLT could critically detect heter-
ogeneity in dexamethasone sensitivity between tumours 
within individual patients. A comparison with  [18F]FDG-
PET was performed in 9 patients treated with neoadju-
vant chemotherapy in a former study and categorised 
according to tumour size assessed by computed tomog-
raphy [29]. Using  [18F]FDG, anatomic responders showed 
significantly lower uptake than anatomic non-responders 
2-3 weeks after treatment, while no significant difference 
was found between these subgroups using  [18F]FLT.
Radiotherapy
Preliminary data of studies that evaluated response to 
radiotherapy is more promising. Vera et  al. [31] dem-
onstrated significant changes in SUVmax in 5 patients 
treated with 46 Gy radiotherapy. This decline of  [18F]FLT 
uptake was supported by another study (n = 20) which 
tested correlation with clinical results after treatment 
with carbon ion radiotherapy [32]. Baseline SUVmax 
was predictive of response as patients who died or devel-
oped recurrence had significantly more  [18F]FLT uptake 
than those did not (p = 0.007 and p = 0.008, respec-
tively). Furthermore, primary tumours showed decreased 
SUVmean and SUVmax despite the absence of morpho-
logical change [33].
Chemoradiotherapy
Three studies have investigated the potential of  [18F]FLT 
for assessing response to chemoradiotherapy. Response 
to chemoradiotherapy was firstly assessed in a small 
study (n = 5), which observed decreased  [18F]FLT uptake 
in primary tumours after therapy [34]. A subsequent 
study (n = 20) found that  [18F]FLT was more sensitive 
than  [18F]FDG in assessing response to radical chemo-
radiation [35]. Median SUVmax were 14 and 6 at base-
line and 10 and 3 two weeks post-therapy for  [18F]FDG 
and  [18F]FLT, respectively. The same group also studied 
correlation with clinical outcome in a larger cohort (n 
= 60) treated with 60 Gy radiotherapy combined with 
carboplatin and paclitaxel or cisplatin (32). Stable dis-
ease, as assessed using RECIST criteria, was associated 
with longer OS and progression-free survival (PFS) than 
patients with complete or partial response. This paradox 
could be ascribed to the weakening of tumouricidal effect 
of chemotherapy by suppressed proliferation [36].
Targeted therapy
Multiple studies have found high potential of  [18F]FLT 
to predict LC response to targeted therapy. Yang et  al. 
analysed the prediction of response to anti-angiogenic 
Fig. 3 Histological association of  [18F]FLT SUVmax and  [18F]FDG SUVmax in different histotypes of LC
Page 16 of 21Alwadani et al. Insights Imaging           (2021) 12:90 
agents in correlation with microvessel density (MVD) 
[37].  [18F]FLT was correlated significantly with MVD as 
reflected by CD105-MVD as well as clinical outcomes. 
Longer median survival times were observed in patients 
who had [18F]FLT false negative results (p = 0.012) and 
in patients with lower CD105-MVD (p = 0.046). Moreo-
ver, the ability of  [18F]FLT to monitor pharmacodynamic 
effect therapy was examined by Scarpelli et al. with static 
(n = 14) and dynamic (n = 33) PET [38, 39]. In the static 
PET study, SUVmax was decreased −11% in cycle 1 
treatment with the anti-angiogenic x-82. After adminis-
tration of cycle 2 x-82 combined with the chemotherapy 
docetaxel on day 21, SUVmax was greatly decreased to 
−44% (34). Decline of cell tumour proliferation and vas-
culature were also exhibited 2 weeks after treatment with 
axitinib followed by an increase in washout period during 
the week of treatment break [39].
Assessment of epidermal growth factor receptor-tyros-
ine kinase inhibitors (EGFR-TKI) response with  [18F]FLT 
is also an active area of research. Typical scans of  [18F]
FLT uptake before and after EGFR-TKI therapy in a LC 
patient responding to therapy are shown in Fig.  4. The 
value of  [18F]FLT in this role is due to well-established 
clinical benefits of EGFR-TKI, as they are being used as 
first-line therapy in select NSCLC patients [47]. Three 
studies investigated the performance of  [18F]FLT in 
assessing tumour progression in correlation with tumour 
size measured by computed tomography. Sohn et al. uti-
lised  [18F]FLT to predict response to gefitinib in 31 ade-
nocarcinoma patients [40]. A significant difference (p < 
0.001) was shown between responders and non-respond-
ers. Mileshkin et al. also evaluated  [18F]FLT and  [18F]FDG 
to monitor response in 51 NSCLC patients 2 and 8 weeks 
after treatment with erlotinib (first generation EGFR-TKI 
drug). 4 responders were assigned by computed tomog-
raphy; all of them were classified responders by  [18F]FDG 
and 3 of them by  [18F]FLT [41]. In contrast, Zander et al. 
found that tumour size measurements correlated with 
changes in  [18F]FDG uptake (p < 0.05) but not with  [18F]
FLT (p > 0.05) 6 weeks after erlotinib therapy [42]. More-
over, further clinical assessment of  [18F]FLT role for early 
monitoring of response to newer generations of EGFR-
TKI agents is still required in order to better understand 
their associated mechanisms of responsiveness and 
resistance [48].
The predictive role of clinical outcome using  [18F]FLT 
uptake was also studied in EGFR-TKI studies and showed 
positive results. Sohn et  al. demonstrated that  [18F]FLT 
responders showed significantly longer TTP (p = 0.0041) 
than non-responders. Further, Scheffler et  al. (n = 40) 
observed that  [18F]FLT could prognostically stratify 
NSCLC patients treated with erlotinib, as patients with 
low uptake had significantly longer survival times (p = 
0.027) than patients with high uptake [44]. Moreover, 
apart from one study with a small patient cohort (n = 15) 
[45],  [18F]FLT uptake was correlated with PFS in multiple 
independent studies with larger cohorts [41–43]. How-
ever, in most studies OS did not correlate with  [18F]FLT 
uptake [42, 45].
Discussion
This paper has reviewed the literature of clinical  [18F]FLT 
applications in LC, and compared the uptake values of 
 [18F]FLT and  [18F]FDG in the various main LC sub-types. 
The review clearly shows that  [18F]FLT is able to provide 
useful data to help diagnose, stage and monitor therapy 
response in LC. However, the value of using  [18F]FLT-
PET in some of these roles is stronger than in others. The 
paper also outlines some novel observations about the 
studies performed to date and provides some recommen-
dations that could help to guide the design of prospective 
clinical studies with  [18F]FLT in LC.
For diagnosis and staging,  [18F]FLT showed better 
specificity and discriminative value between inflam-
matory and malignant LC than  [18F]FDG. The superior 
specificity of  [18F]FLT can be attributed to its highly 
selective uptake in highly proliferating (i.e. malignant) 
cells, providing better differentiation of malignant from 
benign tumours.  [18F]FDG exhibits a slightly lower speci-
ficity than  [18F]FLT due to the high metabolic activity 
of some benign lesions and inflammatory cells which 
use glucose as the main substrate for energy production 
[19]. On the other hand,  [18F]FLT shows significantly 
Fig. 4 Evaluating response to erlotinib therapy with  [18F]FDG-PET 
and  [18F]FLT-PET.  [18F]FDG-PET (a) and  [18F]FLT-PET (c) before start 
of treatment, and  [18F]FDG-PET (b) and  [18F]FLT-PET (d) after 1 week 
of treatment with erlotinib.  [18F]FDG uptake is higher than  [18F]
FLT in the baseline scans. Erlotinib treatment decreases uptake of 
both radiotracers. The  [18F]FLT scan after therapy shows minimal 
uptake indicating that erlotinib is effectively inhibiting proliferation. 
Reprinted with permission from JNM. This research was originally 
published in JNM. Kahraman et al. [43]
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lower uptake and, thus, sensitivity than  [18F]FDG in LC. 
The lower sensitivity of  [18F]FLT is in concordance with 
a previous systematic review and meta-analysis study 
which also deduced that  [18F]FLT is a more specific but 
less sensitive radiotracer than  [18F]FDG [49]. The low 
sensitivity of  [18F]FLT appears to be the reason behind 
its understaging of tumours compared to  [18F]FDG. This 
limitation makes it unable to replace  [18F]FDG in these 
roles, although it may be able to complement  [18F]FDG 
in some situations. The relatively low uptake of  [18F]FLT 
in cancer cells is partly due to the fact that cells do not 
express a specialised transporter to facilitate its trans-
port across the cell membrane;  [18F]FLT either enters 
cells via the general nucleoside transporter hENT1 or 
via passive diffusion [50]. Furthermore, highly proliferat-
ing cells such as bone marrow act as a sink, reducing the 
amount of  [18F]FLT available in the body to be taken up 
by tumours [51]. In contrast, cancer cells tend to take up 
relatively high levels of  [18F]FDG. This is due to multiple 
factors. Firstly, they express specialised receptors such as 
GLUT1, which facilitate the active transport of glucose or 
 [18F]FDG across the cell membrane, and partly due to the 
Warburg effect, which results in relatively high glucose 
metabolism in tumour cells. Secondly, whilst most cancer 
cells are highly metabolically active only a proportion of 
them are proliferating at any time. Finally, inflammatory 
cells are usually present in malignant tumours, which will 
further increase  [18F]FDG uptake in regions of interest.
One interesting suggestion is that using  [18F]FLT and 
 [18F]FDG-PET in combination could potentially pro-
vide better diagnostic performance than the individual 
tracers. Indeed, this strategy showed higher sensitiv-
ity and specificity in diagnosing pulmonary lesions [21]. 
However, this benefit is offset by the higher costs associ-
ated with performing two PET scans and the increased 
radiation burden imposed by this dual tracer approach. 
There is an effective dose equivalent of 0.031 mSv/MBq 
and 0.029mSv/MBq for  [18F]FLT and  [18F]FDG, respec-
tively [52]. When 2 doses of 400 MBq were administered 
by Tian et al. [21] this resulted in a total radiation dose 
per patient of approximately 24 mSv (12.4 from  [18F]
FLT + 11.6 from  [18F]FDG) within a week. Owing to the 
increased radiation dose, the dual tracer strategy should 
be valued favourably only for patients with an equivocal 
diagnosis where the benefit of more confident diagnosis 
could brought to the patient, taking into account the pat-
ent’s clinical characteristics.
An analysis of LC studies to date confirmed that there is 
significantly lower  [18F]FLT uptake than  [18F]FDG uptake 
in all histotypes tested (Fig. 3). This result was expected 
given the defined uptake mechanism for  [18F]FDG in 
tumour cells combined with the Warburg effect, which 
results in tumour cells utilising high amounts of glucose. 
A comparison of  [18F]FDG-SUVmax detected no signifi-
cant difference between the 4 sub-types of LC (p > 0.05). 
However, the statistical power of this analysis is limited 
by the number of SCLC studies performed to date and 
the relative high variation in uptake values between stud-
ies in the other tumour types. Publication of additional 
LC datasets is required to confirm if there is any clear dif-
ferences in  [18F]FDG uptake between LC sub-types. In 
contrast, a comparison of  [18F]FLT-SUVmax between the 
different histotypes observed that  [18F]FLT-SUVmax was 
significantly lower in SCLC than in SqCC (p < 0.05). This 
is a new observation which suggests that there may be 
something subtly different between these LC sub-types. 
There are 3 potential straightforward explanations for 
this observation. The first possibility is that SCLC pro-
liferates at a slower rate. This seems unlikely given that 
SCLC is known to be an aggressive sub-type that grows 
quickly. The second possibility is that there is less cellular 
 [18F]FLT uptake into SCLC, either because these tumours 
have limited access to  [18F]FLT in the blood or because 
less radiotracer can cross the plasma-membrane, per-
haps suggesting that the cells may express fewer hENT 
transporters. The third possibility is that SCLC could 
rely more than SqCC on the de novo pathway to synthe-
sise nucleotides rather than using the salvage pathway 
[53], resulting in less  [18F]FLT uptake into cells via hENT 
transporters. To our knowledge neither of the latter pos-
sibilities have been investigated to date.
Evaluating the potential of  [18F]FLT-PET for assessing 
early response to therapy is a logical step, given the clear 
utility of  [18F]FDG-PET in this role in LC. The rationale 
for using  [18F]FLT-PET to assess therapies that selectively 
affect proliferation is especially compelling, as these 
treatments may inhibit proliferation without affecting 
either metabolic rate or causing tumour shrinkage [54]. 
Only 4 out of the 18 LC response assessment studies 
identified in this review did not observe some utility for 
 [18F]FLT in this role [28, 29, 36, 42]. One of these stud-
ies [28] assessed a chemotherapeutic agent that is antag-
onist to thymidylate synthase. This may impact TK1, 
resulting in poor correlation between  [18F]FLT uptake 
and clinical outcomes [53]. Whilst another study [29], 
which studied platinum-based chemotherapy, showed 
no correlation with CT response. The reason for this 
discrepancy is unknown. These findings suggest that the 
complex effect of cytotoxic therapeutics on cell signal-
ling pathways needs to be fully considered to understand 
how each agent may affect  [18F]FLT uptake into cells. 
Indeed, a previous systematic review that evaluated the 
role of  [18F]FLT as a measure of therapy response in dif-
ferent tumours also concluded that  [18F]FLT-PET is not 
as useful as  [18F]FDG-PET for assessing chemotherapeu-
tic response in NSCLC [55]. However, studies evaluating 
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these types of therapies are still scarce and findings from 
more studies with larger patient cohorts might be more 
conclusive. A chemoradiotherapy study which employed 
 [18F]FLT-PET to evaluate therapy response observed that 
stable disease measurements compared with complete or 
partial response based on CT was associated with longer 
OS and progression-free survival (PFS) [36]. This paradox 
could be ascribed to the weakening of tumouricidal effect 
of chemotherapy by suppressed proliferation [36]. Finally, 
a study evaluating  [18F]FLT-PET to assess EGFR-TKI 
response found no correlation with CT measurements 
[42]. However, this observation may be due to utilisa-
tion of size measurements to assess EGFR-TKI; change in 
tumour size may be delayed or may not occur at all with 
this type of therapy, creating a discrepancy between these 
two different metrics [54].
The most promising application for  [18F]FLT is assess-
ing response to targeted agents that selectively inhibit cell 
proliferation. In this role  [18F]FLT is utilised as a precise 
tool for detecting the effects of antiproliferative thera-
pies. Apart from one study with a small patient cohort (n 
= 15) [45],  [18F]FLT uptake correlated with PFS in mul-
tiple independent studies with larger cohorts [41–43]. 
Interestingly, in most studies OS did not correlate with 
 [18F]FLT uptake [42, 45]. This may be due to the subtly 
different metrics captured by PFS and OS. The OS sta-
tistics may be somewhat compromised by the limited 
number of patients recruited in most of these studies 
and/or the limited follow up time. Indeed, the study with 
the largest patient group (n = 51) and follow up time 
observed correlation between  [18F]FLT uptake and OS 
8 weeks after treatment; the longest follow up time in 
other studies was only 6 weeks [41, 42]. Although OS is 
a gold standard measure to demonstrate clinical efficacy, 
larger patient numbers and longer follow up are required 
to establish  [18F]FLT as a reliable measure of this end-
point [56]. PFS is more advantageous than OS in that it 
assesses both stable disease and responsive disease. This 
renders it a more reasonable clinical measure for targeted 
therapies, which often benefit patients mainly through 
prolonged stable disease rather than tumour shrinkage 
[57]. The assessment of pharmacodynamic endpoints is 
another extremely important function for  [18F]FLT. Scar-
pelli et al. [38, 39] demonstrated that the increase of  [18F]
FLT uptake is apparently caused by the washout period 
during treatment. This type of study, which evaluates the 
pharmacodynamic endpoints, is of great importance to 
develop better understanding of drug resistance mecha-
nisms, as it helps clinicians to tailor more effective treat-
ments and to minimise systematic toxicity caused by 
ineffective drugs [38]. Together, these preliminary find-
ings suggest that  [18F]FLT is a useful tool for evaluating 
response to targeted therapies with anticipated cytostatic 
effects, but further studies with different targeted agents, 
larger patient cohorts and longer follow ups are war-
ranted to fully understand its potential in this role.
The studies mentioned above have multiple limita-
tions. One limitation is that most studies are single-
centre observational studies with small patient cohorts. 
This makes it difficult to know how readily the study 
findings would translate to other research centres or if 
similar results would be obtained using larger patient 
cohorts. While most studies used a relatively simi-
lar imaging protocol, there were no standard instruc-
tions for patient preparation. Some studies encouraged 
patients to drink water before imaging, which would 
help to reduce background radiation, whereas others did 
not. In addition, there were differences between studies 
in tracer dose administered, which is likely to affect the 
signal to background ratio. Most studies utilised static 
scans, with similar times between tracer injection and 
imaging. However, the use of different reconstruction 
techniques and metrics for assessing uptake (e.g. FLT-
max vs FLTmean) would result in subtly different values 
being calculated from the same dataset. It is important 
that methods are optimised and standardised, so that the 
results obtained in one study can be directly compared 
with those from another, and so that multi-centre studies 
can generate equivalent data at all participating centres. 
This issue has been recognised within the PET commu-
nity and has resulted in core labs being set up to ensure 
quality control for PET clinical trials [58]. The limited 
number of studies evaluating LC response to various 
types of treatment affects the conclusiveness of study 
findings. Moreover, size-based measurements were used 
as a standard reference in studies evaluating responses 
to targeted therapy although tumour size would not be 
affected with this type of therapy. OS was also used as 
the gold standard for assessing clinical outcome in stud-
ies evaluating responses to targeted therapy although it 
showed limitations compared with surrogate metrics 
such as PFS. Therefore, extra attention is also needed to 
ensure that the most suitable metrics of clinical outcome 
are used to study such therapies with  [18F]FLT-PET.
Conclusions
1. Overall,  [18F]FLT seems to have better specificity in 
diagnosis and staging but lower sensitivity with sig-
nificantly lower uptake than  [18F]FDG. This signifi-
cant difference was also observed after comparing 
uptake values of both tracers in the main histotypes 
of lung cancer that showed consistence with estab-
lished histological patterns of cell proliferation in 
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both tracers. Therefore,  [18F]FLT cannot be consid-
ered superior to  [18F]FDG for diagnosis and staging.
2. [18F]FLT uptake values of SCLC is considerably lower 
than SqCC. This indicates that SCLC may not be 
suitable for  [18F]FLT imaging studies, due to limited 
radiotracer uptake.
3. [18F]FLT can provide good predictive values in 
patients undergoing radiotherapy or chemoradio-
therapy and looks especially useful for assessing early 
response to targeted therapies.
4. [18F]FLT uptake values correlate well with TTP and 
PFS, but less well with size measurements based on 
computed tomography and OS.
5. [18F]FLT-PET tends to be promising in preliminary 
results of pharmacodynamic endpoints of targeted 
therapy predicting potential resistance which could 
permit better individualisation of treatment plans.
Recommendations
1. More suitable reference standards such as histopa-
thology for studies assessing response to targeted 
therapies are recommended for future studies.
2. TTP or PFS appear to be suitable clinical endpoints 
for  [18F]FLT response assessment studies with tar-
geted agents.
3. Studies should carefully consider which LC sub-type 
is recruited for imaging studies with  [18F]FLT, as 
SCLC sub-type appears to have limited uptake.
4. More  [18F]FLT studies are needed, to further evalu-
ate the potential for this radiotracer to assess early 
response to therapy. This should include studies 
which evaluate different targeted therapies, studies 
which use standardised imaging protocols, multi-
centre studies, and studies with larger patient cohorts 
and longer follow up times.
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